Respond with evidence backing up or going against what was written below.

3.a. What are the goals of pharmacotherapy in this case?

It is the goal of pharmacotherapy to reduce impairment and risk for a 17-year-old female with chronic asthma (Archangelo et al., 2022). It is anticipated that the patient’s breathing will improve and that her symptoms of shortness of breath, wheezing, and cough exacerbations at night will decrease with proper treatment. She will also be free of thrush in her mouth. Consequently, the patient is able to resume and maintain her normal activities, as well as reduce the need for short-acting bronchodilator therapy (Archangelo et al., 2022).

3.b. What non-drug therapies might be useful for this patient?

According to Archangelo et al. (2022), activated epithelial-mesenchymal units and inflammatory mediators contribute to asthma. It is common for chronic airway inflammation and structural changes to occur as a result of triggers such as viral infections in the upper respiratory tract, allergens, exercise, changes in the weather, laughter, exposure to inhaled irritants, gastroesophageal reflux disease (GERD), aspirin, stress, and sulfites (Archangelo et al., 2022). It is essential to provide the patient with information regarding both pharmacological and nonpharmacological approaches in light of this knowledge. Nonpharmacological management methods include warming up before exercise, wearing a face mask or scarf to prewarm or humidify inspired air, and altering one’s diet, such as reducing sodium intake. A number of environmental control measures can be taken to prevent a response, such as the removal of dust, maintaining household humidity, and avoiding pollen (Archangelo et al., 2022). Lastly, rinsing the mouth after each use of fluticasone reduces the thrush the patient is experiencing as a side effect.

3.c. What feasible pharmacotherapeutic alternatives are available for treating this patientàchronic asthma?

With a moderate case of not well-controlled asthma, a reasonable pharmacotherapeutic option would be a combination of medium-dose inhaled corticosteroids and long-acting beta2-adrenergic agonists (Archangelo et al., 2022). Since asthma episodes are generally associated with airflow obstructions within the lungs, it can be reversed spontaneously or in response to appropriate asthma treatment, such as the administration of a fast-acting bronchodilator (Quirt, 2018). Therefore, the patient may continue to use albuterol as necessary. A reevaluation will be conducted in two to six weeks.